TME Pharma Provides Results of Final Exercise of Warrants Y

Additional €854K Raised and Extension of Cash Runway From May Into July 2024 - Seite 2

• ALTME ordinary shares (ISIN: NL0015000YE1): 27,853,843
• Warrants Y (ISIN : NL0015001SS1): 0 (all have either been exercised or expired)
• Warrants Z (ISIN: NL0015001SR3): 3,805,728.

As a reminder, in the first exercise period, from January 10-16, 2024, 974,365 Warrants Y were exercised for €97,436.50, resulting in issuance of 389,746 new ordinary shares and 389,746 Warrants Z.

The first Warrant Z exercise period will run from February 26 to March 22, 2024, with settlement on March 29, 2024. For every 4 Warrants Z held, a holder is entitled to subscribe for 5 new shares at €0.20 per share. Warrants Z may be exercised through June 20, 2025. Outstanding 3,805,728 Warrants Z have potential to raise additional €951,432 if exercised in full before the end of the final exercise period on June 20, 2025.

Additional Information
The characteristics, terms and conditions and dilution resulting from the transaction are summarized in the press releases published on November 24 and November 28, 2023 and in the dedicated Rights Issue page on the TME Pharma website.

Dilution
The table below summarizes the dilution from the new ordinary shares issued today, and the maximum additional dilutive potential for an investor who did NOT participate in the transaction should all potential Warrants Z be exercised. Shareholders who participated fully in the transaction, i.e. who purchased the ABSA Y and subsequently exercise both Warrants Y and Z will not be diluted by this transaction.

Description	Shares to be issued	Total shares outstanding	Dilution (cumulative)	Shareholder starting with 1% on February 22, 2024, would then hold
Outstanding shares on February 22, 2024	-	24,437,861	-	1%
Shares Issued on February 23, 2024, from exercise of 8,539,955 Warrants Y	3,415,982	27,853,843	12.26%	0.88%
Exercise of Warrant Z (latest on June 20, 2025)	4,757,160	32,611,003	25.06%